Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Multiple system atrophy, cerebellar type (MSA-c) is a form of multiple system atrophy (MSA) with predominant cerebellar features (gait and limb ataxia, oculomotor dysfunction, and dysarthria).
Biomarker and diagnostic research for multiple system atrophy, cerebellar type has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
3 clinical trials registered, 3 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
94 publications have been identified in PubMed for multiple system atrophy, cerebellar type. Research spans Diagnostic / Biomarker (35%), Basic Science / Preclinical (21%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 28 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:28 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research | 17 | 21% |
Disease patterns and progression | 14 | 18% |
Patient case studies | 10 | 13% |
Research summaries | 5 | 6% |
Clinical study results | 4 | 5% |
Other research | 2 | 3% |
Fecek C (2026). [PMID: 32809337](https://pubmed.ncbi.nlm.nih.gov/32809337/). *Unknown Journal*. [Epidemiology / Natural History]
Lee JS (2026). [PMID: 41520408](https://pubmed.ncbi.nlm.nih.gov/41520408/). *Parkinsonism Relat Disord*. [Diagnostic / Biomarker]
Schneller M (2026). [PMID: 41770321](https://pubmed.ncbi.nlm.nih.gov/41770321/). *J Neural Transm (Vienna)*. [Review / Meta-Analysis]
Sekiya H (2026). [PMID: 41556315](https://pubmed.ncbi.nlm.nih.gov/41556315/). *Ann Neurol*. [Basic Science / Preclinical]
Alm V (2026). [PMID: 41603480](https://pubmed.ncbi.nlm.nih.gov/41603480/). *Eur J Neurol*. [Epidemiology / Natural History]
Dou X (2026). [PMID: 40859026](https://pubmed.ncbi.nlm.nih.gov/40859026/). *Eur J Nucl Med Mol Imaging*. [Basic Science / Preclinical]
Zhao Y (2026). [PMID: 42206952](https://pubmed.ncbi.nlm.nih.gov/42206952/). *J Parkinsons Dis*. [Epidemiology / Natural History]
Xiao S (2026). [PMID: 41738058](https://pubmed.ncbi.nlm.nih.gov/41738058/). *Neuropsychiatr Dis Treat*. [Review / Meta-Analysis]
Jin N (2026). [PMID: 41198228](https://pubmed.ncbi.nlm.nih.gov/41198228/). *AJNR Am J Neuroradiol*. [Basic Science / Preclinical]
Liu Y (2026). [PMID: 41530546](https://pubmed.ncbi.nlm.nih.gov/41530546/). *J Hum Genet*. [Case Report / Case Series]